Alexion Pharmaceuticals (ALXN) PT Raised to $149 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Alexion Pharmaceuticals (ALXN) PT Lowered to $150 at Oppenheimer
October 24, 2019 9:25 AM EDTOppenheimer analyst Hartaj Singh lowered the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $150.00 (from $165.00) while maintaining a Outperform rating.
The analyst commented, "Alexion (ALXN) reported 3Q19 sales/earnings and provided an investor update on 10/23. The company upgraded its financial guidance for... More
